MX2017003693A - Anticuerpo capaz de neutralizar una sustancia que tiene actividad alternativa para la funcion del factor de coagulacion viii (fviii). - Google Patents

Anticuerpo capaz de neutralizar una sustancia que tiene actividad alternativa para la funcion del factor de coagulacion viii (fviii).

Info

Publication number
MX2017003693A
MX2017003693A MX2017003693A MX2017003693A MX2017003693A MX 2017003693 A MX2017003693 A MX 2017003693A MX 2017003693 A MX2017003693 A MX 2017003693A MX 2017003693 A MX2017003693 A MX 2017003693A MX 2017003693 A MX2017003693 A MX 2017003693A
Authority
MX
Mexico
Prior art keywords
fviii
activity
neutralize
substance
antibody
Prior art date
Application number
MX2017003693A
Other languages
English (en)
Other versions
MX388728B (es
Inventor
Igawa Tomoyuki
Kitazawa Takehisa
Muto Atsushi
Suzuki Tsukasa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2017003693A publication Critical patent/MX2017003693A/es
Publication of MX388728B publication Critical patent/MX388728B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Los presentes inventores intentaron producir anticuerpos que neutralizaran la actividad de una sustancia que tiene una actividad para sustituir funcionalmente el FVIII, que resultaran útiles en métodos para medir la reactividad del FVIII en presencia de sustancias que tuvieran una actividad para sustituir funcionalmente el FVIII. Como resultado, los inventores descubrieron que, mediante el uso de anticuerpos que produjeron, es posible medir con precisión la actividad del FVIII en el plasma de un paciente que padece hemofilia A por medio de un ensayo de coagulación de una sola etapa basado en el APTT, y también es posible medir con precisión el titulador del inhibidor del FVIII en el plasma de un paciente que padece hemofilia A y que ha sido sometido a un tratamiento con inhibidores del FVIII por medio de un ensayo de Bethesda basado en el APTT.
MX2017003693A 2014-09-26 2015-09-24 Anticuerpo capaz de neutralizar una sustancia que tiene actividad alternativa para la funcion del factor de coagulacion viii (fviii). MX388728B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014197207 2014-09-26
PCT/JP2015/076854 WO2016047656A1 (ja) 2014-09-26 2015-09-24 凝固第viii因子(fviii)機能代替活性を有する物質を中和する抗体

Publications (2)

Publication Number Publication Date
MX2017003693A true MX2017003693A (es) 2017-06-26
MX388728B MX388728B (es) 2025-03-20

Family

ID=55581180

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003693A MX388728B (es) 2014-09-26 2015-09-24 Anticuerpo capaz de neutralizar una sustancia que tiene actividad alternativa para la funcion del factor de coagulacion viii (fviii).

Country Status (17)

Country Link
US (1) US11214623B2 (es)
EP (1) EP3199554A4 (es)
JP (2) JP6702877B2 (es)
KR (1) KR102517509B1 (es)
CN (1) CN107108746B (es)
AR (1) AR102092A1 (es)
AU (1) AU2015322662B2 (es)
CA (1) CA2961968C (es)
IL (1) IL251111B (es)
MX (1) MX388728B (es)
MY (1) MY192018A (es)
NZ (1) NZ730611A (es)
RU (1) RU2737145C2 (es)
SG (1) SG11201702259RA (es)
TW (1) TWI700300B (es)
WO (1) WO2016047656A1 (es)
ZA (1) ZA201701844B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
TWI701435B (zh) * 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定fviii的反應性之方法
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
CN110461358A (zh) * 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CN107449925A (zh) * 2017-09-22 2017-12-08 郑州大学第附属医院 一种用于凝血因子viii抑制物检测的缓冲液以及检测方法
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
JP6761142B1 (ja) * 2018-08-01 2020-09-23 ノヴォ ノルディスク アー/エス 改良された血液凝固促進抗体
PL3723858T3 (pl) 2018-12-21 2022-03-07 Kymab Limited Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim
CA3127450A1 (en) * 2019-01-22 2020-07-30 Clemson University Research Foundation Anti-elastin antibodies and methods of use
CN115667515A (zh) * 2020-05-22 2023-01-31 中外制药株式会社 中和具有凝血因子viii(f.viii)功能替代活性的物质的抗体

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
EP0152746B1 (en) 1984-01-12 1991-08-14 Chiron Corporation Hybridoma cell lines and monoclonal antibodies to factor viiic
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
IL89491A0 (en) 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH0332287A (ja) 1989-06-29 1991-02-12 Pioneer Electron Corp 記録媒体演奏装置
WO1991008770A1 (en) 1989-12-11 1991-06-27 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
TW212184B (es) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH05184383A (ja) 1990-06-19 1993-07-27 Dainabotsuto Kk 二重特異性抗体
JPH05199894A (ja) 1990-08-20 1993-08-10 Takeda Chem Ind Ltd 二重特異性抗体および抗体含有薬剤
JPH05304992A (ja) 1991-06-20 1993-11-19 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
JPH06104071A (ja) 1991-08-30 1994-04-15 Jasco Corp 発熱体セラミックス溶接加工方法
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH05203652A (ja) 1992-01-28 1993-08-10 Fuji Photo Film Co Ltd 抗体酵素免疫分析法
JPH05213775A (ja) 1992-02-05 1993-08-24 Otsuka Pharmaceut Co Ltd Bfa抗体
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU7214294A (en) 1993-07-01 1995-01-24 Dade International Inc. Process for the preparation of factor x depleted plasma
AU702250B2 (en) 1994-07-11 1999-02-18 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
JPH10165184A (ja) 1996-12-16 1998-06-23 Tosoh Corp 抗体、遺伝子及びキメラ抗体の製法
US5755446A (en) 1996-12-24 1998-05-26 United Technologies Corporation Seal apparatus between a shaft and a non-linear inner surface of a housing
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック,インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CN1073412C (zh) 1998-03-19 2001-10-24 中国科学院化学研究所 一种高分子微包囊的制备方法
EP1074842A1 (en) 1999-07-21 2001-02-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Catalytic anti-factor VIII allo-antibodies
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
JP4908721B2 (ja) 2000-07-17 2012-04-04 中外製薬株式会社 生理活性を有するリガンドのスクリーニング方法
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
EP1500665B1 (en) 2002-04-15 2011-06-15 Chugai Seiyaku Kabushiki Kaisha METHODS FOR CONSTRUCTING scDb LIBRARIES
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
AU2003303543A1 (en) 2002-12-26 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Agonist antibody against heteroreceptor
WO2004065611A1 (ja) * 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗体の軽鎖スクリーニング方法
KR101235507B1 (ko) 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
GB2400851B (en) 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005035754A1 (ja) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2603264C (en) 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
WO2007011746A2 (en) 2005-07-15 2007-01-25 The University Of Vermont And State Agriculture College Highly sensitive immunoassays and antibodies for detection of blood factor viii
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CA2914170C (en) * 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
AU2007358045A1 (en) 2007-08-23 2009-02-26 Lfb Biotechnologies Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the C1 domain of factor VIII
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
KR101597842B1 (ko) * 2008-01-11 2016-02-25 가부시키가이샤 진 테크노 사이언스 인간화된 항-알파9 인테그린 항체 및 그의 용도
FR2933496B1 (fr) 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
CN101906160A (zh) 2009-06-05 2010-12-08 苏州泽璟生物制药有限公司 一种抗人凝血因子ⅷ单克隆抗体及其制备方法和用途
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
KR101856792B1 (ko) 2009-12-25 2018-05-11 추가이 세이야쿠 가부시키가이샤 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
SG10201505217WA (en) * 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
ES2564281T3 (es) 2012-03-08 2016-03-21 F. Hoffmann-La Roche Ag Formulación de anticuerpos Abeta
CN104937423B (zh) * 2012-09-28 2017-05-24 中外制药株式会社 凝血反应的评价方法
US20160206715A1 (en) * 2013-03-15 2016-07-21 Bullet Biotechnology, Inc. Specific multivalent virus-like particle vaccines and uses thereof
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
TWI701435B (zh) * 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定fviii的反應性之方法
AU2016245887B2 (en) 2015-04-10 2021-09-23 Adimab, Llc. Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
CA2978038A1 (en) 2015-04-17 2016-10-20 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
JP2018123055A (ja) 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第viii因子(fviii)の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第xi因子(fxi)異常症の予防および/または治療に用いられる医薬組成物
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity

Also Published As

Publication number Publication date
RU2017113732A (ru) 2018-10-23
US20170275376A1 (en) 2017-09-28
IL251111A0 (en) 2017-04-30
JPWO2016047656A1 (ja) 2017-07-13
AR102092A1 (es) 2017-02-01
CA2961968C (en) 2023-01-24
TWI700300B (zh) 2020-08-01
CA2961968A1 (en) 2016-03-31
CN107108746B (zh) 2021-06-08
MX388728B (es) 2025-03-20
NZ730611A (en) 2021-12-24
JP6702877B2 (ja) 2020-06-03
ZA201701844B (en) 2021-10-27
TW201619201A (zh) 2016-06-01
KR102517509B1 (ko) 2023-04-04
RU2737145C2 (ru) 2020-11-25
EP3199554A4 (en) 2018-07-18
JP2020108395A (ja) 2020-07-16
SG11201702259RA (en) 2017-04-27
WO2016047656A1 (ja) 2016-03-31
BR112017005801A2 (pt) 2017-12-19
AU2015322662B2 (en) 2020-12-10
KR20170064539A (ko) 2017-06-09
AU2015322662A1 (en) 2017-04-06
MY192018A (en) 2022-07-22
EP3199554A1 (en) 2017-08-02
RU2017113732A3 (es) 2019-01-30
US11214623B2 (en) 2022-01-04
CN107108746A (zh) 2017-08-29
IL251111B (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MX2017003693A (es) Anticuerpo capaz de neutralizar una sustancia que tiene actividad alternativa para la funcion del factor de coagulacion viii (fviii).
CY1125436T1 (el) Αναστολεις dna-pk
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1124096T1 (el) Αντισωματα τα οποια στοχευουν αντιγονο ωριμανσης β-κυτταρων και μεθοδοι χρησης
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
CY1122631T1 (el) Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων
CY1120374T1 (el) Ενεργοποιητες κινασων πυρουβικου για χρηση σε θεραπεια
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
BR112014019331A2 (pt) anticorpos para cd47 e métodos de uso desses
MX2017003635A (es) Metodo para medir la reactividad del factor de coagulacion viii (fviii).
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
MX2016002166A (es) Anticuerpos.
BR112015018851A2 (pt) anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos
MX2016003216A (es) Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
EA201592213A1 (ru) Антитела антирецептор трансферрина и способы их использования
MX375500B (es) Anticuerpos anti-factor del complemento c1q y uso de los mismos.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.